Ambitious Bio, a life sciences and AI infrastructure company building systematic records of human biology for artificial intelligence, announced the launch of Corpus, a comprehensive map of protein presence and relative abundance across healthy human tissues.
The company said Corpus is designed to address a fundamental limitation facing biological AI: much of the human biological data needed to train and evaluate advanced models has never been systematically generated.
Across 181 head-to-head tissue comparisons involving major public reference datasets and published studies, Ambitious said adding Corpus increased the number of detected proteins in every comparison. In a typical matched tissue, the increase ranged from 28% to 78%.
The launch comes as AI developers and biopharmaceutical companies increasingly seek higher-quality biological datasets for drug discovery, target identification, safety analysis, and model training. Unlike language data, which can often be gathered from large existing digital repositories, biological information frequently has to be generated directly from physical specimens and standardized across people, tissues, health states, and time.
Ambitious is backed by $6 million in seed funding and was created around the idea of generating biological evidence from first principles rather than relying primarily on information produced as a byproduct of existing healthcare and commercial systems.
For its first product, the company focused on healthy human tissue at the protein level.
While the genome indicates what proteins the body is capable of producing, proteins represent much of the biological machinery actually operating within cells and tissues. They are particularly important to pharmaceutical research because many medicines are designed to interact with a specific protein target.
Developers generally want a therapeutic target to be highly expressed in diseased tissue while having limited presence in critical healthy tissues. When that separation is incomplete, understanding where else the protein appears and at what levels can help researchers evaluate the potential for unintended effects.
Ambitious said Corpus provides a more detailed healthy-tissue baseline that researchers can use to understand disease-related changes and identify locations where a drug could potentially interact with healthy tissue.
In a matched comparison with the Human Protein Atlas, one of the field’s most widely used protein references, Ambitious said Corpus expanded the identified protein inventory by 56% in the median shared tissue. That represents 56 additional proteins detected for every 100 previously known in a comparable tissue.
Ambitious also compared Corpus with the next six largest reference datasets. According to the company, Corpus revealed 79% to 138% more protein types in the median tissue that had not previously been visible through those references.
The additional information could have practical implications for drug development, where failures that occur late in clinical testing can consume significant capital and years of research.
Corpus is intended to help researchers evaluate potential safety issues earlier by identifying where a protein being targeted in diseased tissue, or another sufficiently similar protein that could accidentally interact with the same medicine, also appears in healthy tissues.
Ambitious demonstrated this use case by analyzing 973 proteins currently being pursued as drug targets but not yet addressed by an approved medicine.
For 19% of these targets, the Human Protein Atlas showed no detectable healthy-tissue expression, while Corpus identified healthy expression for the first time. For 77% of the targets, Corpus significantly expanded the number of healthy tissues in which protein expression was detected.
The company believes this broader visibility could help drug developers investigate potential risks before committing substantial capital and limited clinical trial capacity to a candidate.
Corpus currently begins with healthy human proteomics, but Ambitious said it is extending the underlying system across disease biology, additional molecular modalities, other organisms, and increasingly higher-resolution measurements.
The company’s broader goal is to establish infrastructure capable of continuously generating the proprietary biological evidence needed to train, adapt, and evaluate increasingly capable AI models.
Ambitious also argues that biological data infrastructure could become strategically important at a national level. Unlike internet-scale language datasets, reliable biological measurements generally cannot simply be collected from existing online information. They require laboratory infrastructure, physical specimens, measurement systems, and standardized data-generation processes.
As AI increasingly moves from language and software into biology, Ambitious believes organizations capable of generating high-quality proprietary biological data at scale could develop an important competitive advantage in areas including drug discovery, diagnostics, prevention, biotechnology, and biological AI.
KEY QUOTES:
“We have complete bills of material for cars, wristwatches and toasters, down to the last screw. We still don’t have the same for the human body. As AI becomes more capable of designing interventions into biology, the value of a more complete map of the system it’s trying to change only increases.”
Elizabeth Hudson, Founder and CEO of Ambitious
“The lesson Apple demonstrated most clearly is that the most consequential products become foundations for entirely new industries. Ambitious is building that foundation as AI moves beyond language into biology, where there is no internet of reliable data waiting to be scraped; it has to be generated. China is building that capacity at scale, and any nation that wants to compete in biological AI will need to do the same.”
Jeff Martin, Board Member at Ambitious
“The power of Ambitious is not data, but the machine we built to generate what biological intelligence needs next. As the frontier becomes more competitive, durable advantages will increasingly come from the proprietary evidence used to train, adapt and evaluate them. Better biological measurements enable better models. Better models more efficiently select more informative hypotheses and experiments. Those experiments beget still more valuable data.”
Elizabeth Hudson, Founder and CEO of Ambitious
